Shanghai-based EpimAb Bio grows global roots with $25M A round and a key assist by Robert Kamen
In another sign that China’s up-and-coming biotech community continues to gather steam, an upstart called EpimAb Biotherapeutics has hauled in a $25 million A round …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
